Sickle cell disease trials recruiting in Georgia

All Sickle cell disease trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Long-term Follow-up Study in Patients Who Received BEAM-101
  NCT07373639 · Phase: Not specified · Ages: 14 Years to 37 Years · Sex: All (male and female) · Georgia: Atlanta
• A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
  NCT07187973 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Augusta
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Georgia: Atlanta, Dunwoody, Riverdale
• A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  NCT06609226 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · Georgia: Atlanta, Augusta
• A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
  NCT06290401 · Phase: Not applicable (e.g. observational or device study) · Ages: 13 Years to 21 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Georgia: Atlanta
• A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
  NCT06439082 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Georgia: Augusta, Riverdale
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
  NCT04398628 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Georgia: Atlanta, Savannah
• Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
  NCT02447874 · Phase: Phase 1, Phase 2 · Ages: 7 Years to 21 Years · Sex: All (male and female) · Georgia: Atlanta
• Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing
  NCT07562451 · Phase: Not applicable (e.g. observational or device study) · Ages: 8 Years to 18 Years · Sex: All (male and female) · Georgia: Atlanta
• Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
  NCT06665997 · Phase: Phase 4 · Ages: 18 Years to 50 Years · Sex: Female · Georgia: Atlanta
• Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
  NCT06941389 · Phase: Not specified · Ages: 3 Years to 20 Years · Sex: All (male and female) · Georgia: Atlanta
• Cooperative Assessment of Late Effects for SCD Curative Therapies
  NCT05153967 · Phase: Not specified · Ages: 4 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta
• Integrative Training Program for Pediatric Sickle Cell Pain
  NCT06691867 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 18 Years · Sex: All (male and female) · Georgia: Atlanta
• Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
  NCT06374238 · Phase: Not applicable (e.g. observational or device study) · Ages: 16 Years to 30 Years · Sex: All (male and female) · Georgia: Atlanta
• Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
  NCT06979492 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · Georgia: Atlanta
• Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
  NCT06385886 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Augusta
• Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
  NCT04657822 · Phase: Phase 4 · Ages: 6 Months to 100 Years · Sex: All (male and female) · Georgia: Augusta
• Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
  NCT07252050 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 45 Years · Sex: All (male and female) · Georgia: Atlanta
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  NCT07224360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Georgia: Atlanta
• Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
  NCT01245179 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Augusta
• Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
  NCT07247188 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
  NCT07090668 · Phase: Not applicable (e.g. observational or device study) · Ages: 7 Years to 18 Years · Sex: All (male and female) · Georgia: Atlanta